Abstract
Invasive infections caused by Streptococcus pneumoniae, such as pneumonia, meningitis, and bacteremia, are a major cause of morbidity and mortality in young children and older adults worldwide. The introduction of pneumococcal conjugate vaccines into national childhood immunization programs has led to large and sustained reductions in the incidence of invasive pneumococcal disease across all age groups. Here we describe the epidemiology and biostatistics of pneumococcal disease as well as the impact of vaccination on the burden of pneumococcal disease globally.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Russel F, Sanderson C, Temple B, Mulholand K (2011) Global review of the distribution of pneumococcal disease by age and region. World Health Organization, Geneva, Switzerland. http://www.who.int/immunization/sage/6_Russel_review_age_specific_epidemiology_PCV_schedules_session_novl 1.pdf. 2011.Nov
Drijkoningen JJ, Rhode GG (2014) Pneumococcal infection in adults: burden of disease. Clin Microbiol Infect 20:45–51
Advisory Committee on Immunization Practices (2000) Preventing pneumococcal disease among infants and young children. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 49(RR-9):1–35
Butler JC, Schuchat A (1999) Epidemiology of pneumococcal infections in the elderly. Drugs Aging 15(Suppl 1):11–19
Walker CL, Rudan I, Liu L, Nair H, Theodoratou E, Bhutta ZA et al (2013) Global burden of childhood pneumonia and diarrhoea. Lancet 381(9875):1405–1416
World Health Organization (2008) Estimated Hib and pneumococcal deaths for children under 5 years of age. http://www.who.int/immunization/monitoring_surveillance/burden/estimates/Pneumo_hib/en/. Accessed 12 May
O’Brien KL, Wolfson LJ, Watt JP, Henkle E, Deloria-Knoll M, McCall N et al (2009) Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates. Lancet 374(9693):893–902
Mackenzie GA, Hill PC, Jeffries DJ, Hossain I, Uchendu U, Ameh D et al (2016) Effect of the introduction of pneumococcal conjugate vaccination on invasive pneumococcal disease in The Gambia: a population-based surveillance study. Lancet Infect Dis 16(6):703–711
Izurieta P, Bahety P, Adegbola R, Clarke C, Hoet B (2018) Public health impact of pneumococcal conjugate vaccine infant immunization programs: assessment of invasive pneumococcal disease burden and serotype distribution. Expert Rev Vaccines 17(6):479–493
Kyaw MH, Christie P, Clarke SC, Mooney JD, Ahmed S, Jones IG et al (2003) Invasive pneumococcal disease in Scotland, 1999–2001: use of record linkage to explore associations between patients and disease in relation to future vaccination policy. Clin Infect Dis 37:1283–1291
Reinert RR, Haupts S, van der LM HC, Cil MY, Al-Lahham A et al (2005) Invasive pneumococcal disease in adults in North-Rhine Westphalia, Germany, 2001–2003. Clin Microbiol Infect 11:985–991
Lynch JP, Zhanel GG (2009) Streptococcus pneumoniae: epidemiology, risk factors, and strategies for prevention. Semin Respir Crit Care Med 30:189–209
Jackson ML, Neuzil KM, Thomson WW et al (2004) The burden of community-acquired pneumonia in seniors: results of a population-based study. Clin Infect Dis 39:1642–1650
Vila-Corcoles A, Ochoa-Gondar O, Llor C, Rodríguez T, Gómez A (2005) Protective effect of pneumococcal vaccine against death by pneumonia in elderly subjects. Eur Respir J 26(6):1086–1091
El-Solh AA, Sikka P, Ramadan F, Davies J (2001) Etiology of severe pneumonia in the very elderly. Am J Respir Crit Care Med 163(3 Pt 1):645–651
Maimaiti N, Ahmed Z, Isa ZM, Ghazi HF, Aljunid S (2013) Clinical burden of invasive pneumococcal disease in selected developing countries. Value Health Reg Issues 2(2):259–263
Weycker D, Strutton D, Edelsberg J, Sato R, Jackson LA (2010) Clinical and economic burden of pneumococcal disease in older US adults. Vaccine 28:4955–4960
Huang SS, Johnson KM, Ray GT et al (2011) Healthcare utilization and cost of pneumococcal disease in the United States. Vaccine 29:3398–3412
Gibson GJ, Loddenkemper R, Sibille Y, European Respiratory Society/European Lung Foundation (2003) Lung Health in Europe Facts and Figures. ERSJ, Sheffield
Davis SM, Deloria-Knoll M, Kassa HT, O’Brien KL (2013) Impact of pneumococcal conjugate vaccines on nasopharyngeal carriage and invasive disease among unvaccinated people: review of evidence on indirect effects. Vaccine 32:133–145
Hennessy TW, Singleton RJ, Bulkow LR et al (2005) Impact of heptavalent pneumococcal conjugate vaccine on invasive disease, antimicrobial resistance and colonization in Alaska Natives: progress towards elimination of a health disparity. Vaccine 23:5464–5473
Cohen R, Levy C, Bingen E, Bonnet E, Koskas M, Attal S, et al (2011) Impact of 13-valent pneumococcal conjugate vaccine (PCV13) on nasopharyngeal (NP) flora in children with acute otitis media (AOM). In: Presented at the 51st ICAAC, September 17–20, 2011, Chicago, USA
Conklin L, Loo JD, Kirk J, Fleming-Dutra KE, Deloria Knoll M, Park DE et al (2014) Systematic review of the effect of pneumococcal conjugate vaccine dosing schedules on vaccine-type invasive pneumococcal disease among young children. Pediatr Infect Dis J 33(Suppl 2 Optimum Dosing of Pneumococcal Conjugate Vaccine For Infants 0 A Landscape Analysis of Evidence Supporting Different Schedules):S109–S118
Kaplan SL, Barson WJ, Lin PL, Romero JR, Bradley JS, Tan TQ et al (2013) Early trends for invasive pneumococcal infections in children after the introduction of the 13-valent pneumococcal conjugate vaccine. Pediatr Infect Dis J 32:203–207
Waight PA, Andrews NJ, Ladhani SN, Sheppard CL, Slack MPE, Miller E (2015) Effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 years after its introduction: an observational cohort study. Lancet Infect Dis 15(5):535–543
Gilmour R, Holland R, Kampen R, Brown M, Gilbert L, Hogg G et al (2008) Invasive pneumococcal disease in Australia, 2006. Commun Dis Intell 32(1):18–30
Kellner JD, Church DL, MacDonald J, Tyrrell GJ, Scheifele D (2005) Progress in the prevention of pneumococcal infection. Can Med Assoc J 173(10):1149–1151
Zangeneh TT, Baracco G, Al-Tawfiq JA (2011) Impact of conjugate pneumococcal vaccines on the changing epidemiology of pneumococcal infections. Expert Rev Vaccines 10(3):345–353
World Health Organization position paper - Pneumococcal conjugate vaccine for childhood immunization (2007) WHO position paper. Wkly Epidemiol Rec 82(12):93–104
Myint TT, Madhava H, Balmer P, Christopoulou D, Attal S, Menegas D et al (2013) The impact of 7-valent pneumococcal conjugate vaccine on invasive pneumococcal disease: a literature review. Adv Ther 30(2):127–151
Miller E, Andrews NJ, Waight PA, Slack MPE, George RC (2011) Herd immunity and serotype replacement 4 years after seven-valent pneumococcal conjugate vaccination in England and Wales: an observational cohort study. Lancet Infect Dis 11(10):760–768
Weinberger DM, Malley RLM (2011) Serotype replacement in disease after pneumococcal vaccination. Lancet 378(9807):1962–1973
Singleton RJ, Hennessy TW, Bulkow LR, Hammitt LL, Zulz T, Hurlburt DA et al (2007) Invasive pneumococcal disease caused by nonvaccine serotypes among Alaska native children with high levels of 7-valent pneumococcal conjugate vaccine coverage. JAMA 297(16):1784–1792
Park SY, Van Beneden CA, Pilishvili T, Martin M, Facklam RR, Whitney CG (2010) Invasive pneumococcal infections among vaccinated children in the United States active bacterial core surveillance team. J Pediatr 158(3):478–483.e2
Ben-Shimol S, Givon-Lavi N, Grisaru-Soen G, Megged O, Greenberg D, Dagan R (2017) Comparative incidence dynamics and serotypes of meningitis, bacteremic pneumonia and other-IPD in young children in the PCV era: Insights from Israeli surveillance studies. Vaccine 36(36):5477–5484
Alari A, Chaussade H, Domenech De Cellès M, Le Fouler L, Varon E, Opatowski L et al (2016) Impact of pneumococcal conjugate vaccines on pneumococcal meningitis cases in France between 2001 and 2014: a time series analysis. BMC Med 14(1):211
Hsu HE, Shutt KA, Moore MR, Beall BW, Bennett NM, Craig AS et al (2009) Effect of pneumococcal conjugate vaccine on pneumococcal meningitis. N Engl J Med 360(3):244–256
Ruiz-Contreras J, Picazo J, Casado-Flores J, Baquero-Artigao F, Hernández-Sampelayo T, HERACLES STUDY GROUP et al (2017) Impact of 13-valent pneumococcal conjugate vaccine on pneumococcal meningitis in children. Vaccine 35(35 Pt B):4646–4651
Tsai CJ, Griffin MR, Nuorti JP, Grijalva GC (2008) Changing epidemiology of pneumococcal meningitis after introduction of pneumococcal conjugate vaccine in the United States. Clin Infect Dis 46(11):1664–1672
Olarte L, Barson WJ, Barson RM, Lin PL, Romero JR, Tan TQ et al (2015) Impact of the 13-valent pneumococcal conjugate vaccine on pneumococcal meningitis in US children. Clin Infect Dis 61(5):767–775
Jacobs M (2008) Antimicrobial-resistant streptococcus pneumoniae: trends and management. Expert Rev Anti-Infect Ther 6(5):619–635
Park IH, Moore MR, Treanor JJ, Pelton SI, Pilishvili T, Beall B et al (2008) Active bacteria core surveillance team. Differential effects of pneumococcal vaccines against serotypes 6A and 6C. J Infect Dis 198(12):1818–1822
Pelton SI, Huot H, Finkelstein JA, Bishop CJ, Hsu KK, Kellenberg J et al (2007) Emergence of 19A as virulent and multidrug resistant Pneumococcus in Massachusetts following universal immunization of infants with pneumococcal conjugate vaccine. Pediatr Infect Dis J 26(6):468–472
Pai R, Moore MR, Pilishvili T, Gertz RE, Whitney CG, Beall B (2005) Postvaccine genetic structure of Streptococcus pneumoniae serotype 19A from children in the United States. J Infect Dis 192(11):1988–1995
Yildirim I, Stevenson A, Hsu KK, Pelton SI (2012) Evolving picture of invasive pneumococcal disease in Massachusetts children: a comparison of disease in 2007–2009 with earlier periods. Pediatr Infect Dis J 31(10):1016–1021
Vanderkooi OG, Scheifele DW, Girgenti D, Halperin SA, Patterson SD, Gruber WC et al (2012) Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine in healthy infants and toddlers given with routine pediatric vaccinations in Canada. Pediatr Infect Dis J 31(1):72–77
European Centre for Disease Prevention and Control (2017) Invasive pneumococcal disease. Stockholm. https://ecdc.europa.eu/en/publications-data/invasive-pneumococcal-disease-annual-epidemiological-report-2017. Accessed 12 May 2018
World Health Organization, UNICEF (2013) Ending preventable child deaths from pneumonia and diarrhoea by 2025: The integrated Global Action Plan for Pneumonia and Diarrhoea (GAPPD)
Troeger C, Forouzanfar M, Rao PC, Khalil I, Brown A, Reiner RC Jr et al (2017) Estimates of global, regional, and national morbidity, mortality, and aetiologies of diarrhoeal diseases: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Infect Dis 3099(17):1–40
Lucero M, Dulalia V, Nillos L, Williams G, Parreño R, Nohynek H et al (2009) Pneumococcal conjugate vaccines for preventing vaccine-type invasive pneumococcal disease and X-ray defined pneumonia in children less than two years of age. Cochrane Database Syst Rev 4:CD004977
Ewald H, Briel M, Vuichard D, Kreutle V, Zhydkov A, Gloy V (2016) The clinical effectiveness of pneumococcal conjugate vaccines: a systematic review and metaanalysis of randomized controlled trials. Dtsch Arztebl Int 113(9):139–146
Whitney CG, Farley MM, Hadler J, Harrison LH, Lexau C, Reingold A et al (2000) Active bacterial core surveillance program of the emerging infections program network. Increasing prevalence of multidrug-resistant streptococcus pneumoniae in the United States. N Engl J Med 343(26):1917–1924
Richter SS, Heilmann KP, Dohrn CL, Riahi F, Diekema DJ, Doern GV (2013) Pneumococcal serotypes before and after introduction of conjugate vaccines, United States, 1999–2011. Emerg Infect Dis 19(7):1074–1083
Hanquet G, Kissling E, Fenoll A, George R, Lepoutre A, Lernout T et al (2010) Pneumococcal serotypes in children in 4 European countries. Emerg Infect Dis 16(9):1428–1439
Janoir C, Lepoutre A, Gutmann L, Varon E (2016) Insight into resistance phenotypes of emergent non 13-valent pneumococcal conjugate vaccine type pneumococci isolated from invasive disease after 13-valent Pneumococcal conjugate vaccine implementation in France. Open Forum Infect Dis 3(1):ofw020
Mahjoub-Messai F, Doit C, Koeck JL, Billard T, Evrard B, Bidet P et al (2009) Population snapshot of Streptococcus pneumoniae serotype 19A isolates before and after introduction of seven-valent pneumococcal vaccination for French children. J Clin Microbiol 47(3):837–840
Cohen C, von Mollendorf C, de Gouveia L, Naidoo N, Meiring S, Quan V et al (2014) Effectiveness of 7-valent pneumococcal conjugate vaccine against invasive pneumococcal disease in HIV-infected and -uninfected children in South Africa: a matched case-control study. Clin Infect Dis 59:808–818
Von Gottberg A, de Gouveia L, Tempia S, Quan V, Meiring S, Von Mollendorf C et al (2014) Effects of vaccination on invasive pneumococcal disease in South Africa. N Engl J Med 371(20):1889–1899
Moore MR, Link-Gelles R, Schaffner W et al (2016) Effectiveness of 13- valent pneumococcal conjugate vaccine for prevention of invasive pneumococcal disease in children in the USA: a matched case- control study. Lancet Respir Med 4:399–406
Isturiz R, Sings HL, Hilton B, Arguedas A, Reinert RR, Jodar L (2017) Streptococcus pneumoniae serotype 19A: worldwide epidemiology. Expert Rev Vaccines 16(10):1007–1027
Gaviria-Agudelo CL, Jordan-Villegas A, Garcia C, McCracken GH Jr (2017) The effect of 13-valent pneumococcal conjugate vaccine on the serotype distribution and antibiotic resistance profiles in children with invasive pneumococcal disease. J Pediatr Infect Dis Soc 6(3):253–259
Balsells E, Guillot L, Nair H, Kyaw MH (2017) Serotype distribution of Streptococcus pneumoniae causing invasive disease in children in the post-PCV era: A systematic review and meta-analysis. PLoS One 12(5):e0177113
Tomczyk S, Bennett NM, Stoecker C, Gierke R, Moore MR, Whitney CG, Centre for Disease Control and Prevention (CDC) et al (2014) Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged ≥65 years: recommendations of the Advisory Committee on Immunization Practices (ACIP). Morb Mortal Wkly Rep 63:822–825
Persons I (2013) Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among children aged 6–18 years with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP). Morb Mortal Wkly Rep 62(25):521
Huss A, Scott P, Stuck AE, Trotter C, Egger M (2009) Efficacy of pneumococcal vaccination in adults: a meta-analysis. Can Med Assoc J 180:48–58
Poolman J, Borrow R (2011) Hyporesponsiveness and its clinical implications after vaccination with polysaccharide or glycoconjugate vaccines. Expert Rev Vaccines 10:307–322
VIEW-hub [Internet]. PCV: Current vaccine intro status. [Cited 2018 May12]. http://view-hub.org/viz/
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Science+Business Media, LLC, part of Springer Nature
About this protocol
Cite this protocol
Oligbu, G., Fry, N.K., Ladhani, S.N. (2019). The Epidemiology and Biostatistics of Pneumococcus. In: Iovino, F. (eds) Streptococcus pneumoniae. Methods in Molecular Biology, vol 1968. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-9199-0_18
Download citation
DOI: https://doi.org/10.1007/978-1-4939-9199-0_18
Published:
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4939-9198-3
Online ISBN: 978-1-4939-9199-0
eBook Packages: Springer Protocols